Craft

NLS Pharmaceutics

Stock Price

$4.1

2024-10-29

Market Capitalization

$10.2 M

2024-10-29

NLS Pharmaceutics Summary

Company Summary

Overview
NLS Pharmaceutics is a biopharmaceutical company engaged in drug discovery for central nervous system disorders. It is focused on the development of therapeutics for neurobehavioral and neurocognitive disorders including attentional disorders, excessive daytime sleepiness, pervasive developmental disorders, cognitive impairments, and synucleopathies.
Type
Public
Status
Active
Founded
2019
HQ
Stans, CH | view all locations
Website
https://nlspharma.com
Cybersecurity rating
Sectors

Key People

  • Alex Zwyer

    Alex Zwyer, President & Chief Executive Officer

  • Silvia Panigone

    Silvia Panigone, Interim Chief Operating Officer

  • Subhasis Roy

    Subhasis Roy, Interim Chief Financial Officer

    Operating MetricsView all

    Drugs Approved by FDA

    6

    Feb, 2021

    Patents and Patent Applications

    5

    Feb, 2021

    LocationsView all

    1 location detected

    • Stans, NW HQ

      Switzerland

      Alter Postpl. 2

    NLS Pharmaceutics Financials

    Summary Financials

    Gross profit (FY, 2024)
    $2.5M
    Net income (FY, 2024)
    ($2.0M)
    Cash (FY, 2024)
    $1.7M
    EBIT (FY, 2024)
    ($1.8M)

    Footer menu